October 2024 – Page 3

Novartis Secures FDA Approval for Scemblix as First-Line Treatment for Newly Diagnosed CML, Anticipates $3B in Peak Sales

6 months ago talkbio0Tagged Approved, first-line, Inhibitor, Myeloid Leukemia, Chronic, Novartis, Scemblix, TTLL5 gene, Tyrosine Kinase Inhibitors [MoA], United States Food and Drug Administration

Novartis, Scemblix, FDA Approval, First-Line Treatment, CML, Chronic Myeloid Leukemia, ASC4FIRST Trial, Tyrosine Kinase Inhibitors, STAMP Inhibitor

Pfizer Boosts Revenue Forecast by $1.5 Billion Amid Paxlovid Rebound, Despite Criticism from Starboard

6 months ago talkbio0Tagged COVID19 (disease), financial performance, Paxlovid, Pfizer, Starboard

Pfizer, revenue outlook, Paxlovid, Starboard, pharmaceuticals, COVID-19, financial performance

Astellas Withdraws European Application for Geographic Atrophy Treatment Izervay

6 months ago talkbio0Tagged Application procedure, Astellas, avacincaptad, European (ethnic group), Geographic Atrophy, IZERVAY, pegol

Astellas, Izervay, geographic atrophy, European application withdrawal, avacincaptad pegol

Iambic Therapeutics Enhances AI Suite with “Enchant” for Predictive Preclinical Drug Development

6 months ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, clinical success, Drug Discovery, Enchant, Iambic, preclinical predictive powers, Prediction

Iambic Therapeutics, AI, Enchant, preclinical predictive powers, drug discovery, clinical success prediction

Crescent Biopharma’s Public Debut Fueled by PD-1/VEGF Combination Therapy Enthusiasm

6 months ago talkbio0Tagged biopharmaceutical industry, Combined Modality Therapy, inhibitors, Malignant Neoplasms, PD-1/PD-L1, Public Listing, Vascular Endothelial Growth Factor A

PD-1/PD-L1 inhibitors, VEGF inhibitors, Combination therapy, Cancer treatment, Biopharmaceutical industry, Public listing

Modified Dosing Regimen of Eli Lilly’s Alzheimer’s Drug Kisunla (Donanemab) Reduces Brain Swelling

6 months ago talkbio0Tagged Alzheimer 's disease, amyloid-related imaging abnormalities, ARIA-E, Cerebral Edema, Changing, Donanemab, dosing, Eli, Eli Lilly, Kisunla, oedema/effusion, TRAILBLAZER-ALZ, Treatment Protocols, Trial Phase 3B

Alzheimer’s disease, Eli Lilly, Kisunla (donanemab), Modified dosing regimen, ARIA-E (amyloid-related imaging abnormalities with oedema/effusion), Brain swelling, TRAILBLAZER-ALZ 6 Phase IIIb trial

Novartis’ $2.9B MorphoSys Acquisition Hits Roadblock as Safety Concerns Delay Approval Filing

6 months ago talkbio0Tagged delayed approval, MorphoSys, Novartis, Safety, Signal

Novartis, MorphoSys, safety signal, delayed approval, biotech, pharmaceuticals

GSK Expands Lupus Portfolio with $300M Upfront Deal for T-Cell Engager

6 months ago talkbio0Tagged Autoimmune Diseases, Biosciences, Chimagen, Lupus Vulgaris, pharmaceutical deals, SmithKline Beecham, T-Lymphocyte

GSK, lupus, T-cell engager, Chimagen Biosciences, autoimmune diseases, pharmaceutical deals

Biopharma Industry Alarmed by Prospect of RFK Jr. Shaping FDA Policies Under Trump Administration

6 months ago talkbio0Tagged Administration occupational activities, Agriculture, Biopharma, Health care facility, Policy, RFK Jr., Transplant Registry Unified Management Program, United States Food and Drug Administration

RFK Jr., FDA, Trump Administration, Biopharma, Healthcare Policy, Agriculture Policy

WuXi AppTec Continues to Attract New Clients Amid BIOSECURE Act Uncertainty

6 months ago talkbio0Tagged AppTec, BIOSECURE, chain vulnerabilities, Chinese, Chinese contract manufacturer, Clients, Drug Industry, Senate consideration, WuXi

WuXi AppTec, BIOSECURE Act, new clients, revenue decline, Chinese contract manufacturer, U.S. Senate consideration, pharmaceutical industry, supply chain vulnerabilities.